# A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)

> **NCT01727271** · PHASE4 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Tenofovir
- **BIOLOGICAL:** Pegylated interferon alpha-2b

## Key facts

- **NCT ID:** NCT01727271
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-08
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01727271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01727271, "A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01727271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*